Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Drs Bustamante and Stine discuss their journeys toward oncology careers, the importance of peer mentorship, and the evolving nature of work-life balance.

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.

The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.

Florida Cancer Specialists & Research Institute spotlights a study uncovering a new testing method to determine personalized care options in NSCLC.

Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami.

Florida Cancer Specialists & Research Institute physicians are participating in the FLASCO 2024 Business of Oncology Summit & Spring Session to discuss topics impacting community oncology.

A case study details the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival.

A case study showed community oncology practices emerged as the preferred site of service for cancer treatment.

Florida Cancer Specialists & Research Institute, LLC announces the introduction of designated Disease SiteTeams for late-phase research & the subsequent formation of the FCS Disease Site Committee.

Florida Cancer Specialists & Research Institute, LLC is calling for reform in value-based oncology care modeling.

Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC was highlighted at the 2024 AACR Annual Meeting.

In the wake of the cyberattack and subsequent outage of Change Healthcare, Florida Cancer Specialists & Research Institute stands resolute in its commitment to patient care and safety.

FCS is pleased to announce that medical oncologist and hematologist Jacob L. Barish, MD, has joined the statewide practice.

Florida Cancer Specialists & Research Institute has opened a new facility in Orange City, FL, to provide comprehensive cancer care.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD, FACOG, FACS has joined the statewide practice.

Florida Cancer Specialists & Research Institute, LLC announces the appointments of Joel Grossman, MD and Maen Hussein, MD to its Executive Board.

Florida Cancer Specialists & Research Institute announces their intentions to explore a new distributor and group purchasing organization partnerships.

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.

The National Accreditation Program for Breast Centers has granted the Florida Cancer Specialists & Research Institute breast cancer program a 3-year accreditation.

A program developed at Florida Cancer Specialists & Research Institute improves outcomes for patients prescribed selinexor for multiple myeloma.

Robin Marshall's "most valuable" painting was recently purchased by her oncologist, Alpana Desai, MD, of Florida Cancer Specialists & Research Institute.

The Florida Cancer Specialists & Research Institute, LLC 2022 Annual Report has been recognized in the 4th Annual Healthcare Digital Marketing Awards.

The value-based care program offers Florida patients access to high quality cancer care while reducing costs for employers